MC
SCPH

Matisse Capital’s scPharmaceuticals SCPH Stock Holding History

Matisse Capital’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-17,685
Closed -$132K – 165
2020
Q3 		$132K Hold
17,685
– – 0.05% 136
2020
Q2 		$130K Sell
17,685
-10,000
-36% -$87.8K 0.04% 148
2020
Q1 		$205K Buy
27,685
+13,000
+89% +$94.3K 0.08% 154
2019
Q4 		$83K Hold
14,685
– – 0.06% 112
2019
Q3 		$86K Buy
+14,685
New +$82.8K 0.11% 94

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Matisse Capital's SCPH Position: Q4 2020 in Review

Matisse Capital sold out of scPharmaceuticals (SCPH) in Q4 2020, closing a stake of 17,685 shares — an estimated $132K sold.

Matisse Capital first reported a position in SCPH in Q3 2019 and held it in 5 quarters. The position peaked at $205K in Q1 2020. 47 funds tracked by Wall St. Rank hold SCPH as of Q4 2020.

  • Matisse Capital reported no remaining scPharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Matisse Capital sold 17,685 scPharmaceuticals shares in Q4 2020, an estimated $132K.
  • Matisse Capital first reported a position in scPharmaceuticals in Q3 2019 and held it in 5 quarters.
  • Matisse Capital's scPharmaceuticals position peaked at $205K in Q1 2020.
  • 47 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2020.

Based on Matisse Capital's 13F filing for Q4 2020, filed 12 Feb 2021.